Endowment / Foundation

Updated:

Genome BC

Genome BC was founded in 2000 as a not-for-profit catalyst for genomics innovation in British Columbia. President and CEO Suzanne Gill leads an organization...

Genome BC logo

Genome BC

Genome BC was founded in 2000 as a not-for-profit catalyst for genomics innovation in British Columbia. President and CEO Suzanne Gill leads an organization that bridges academic research and industrial application, co-funded by Genome Canada and the Province of British Columbia. Its mandate spans seven sectors, applying genomics to challenges in health, forestry, fisheries, agriculture, energy, mining, and the environment. The organization deploys capital across early-stage and venture opportunities through a hybrid model of research grants and direct commercialization support. Its investment posture translates genomic discoveries into applied solutions — spanning digital health diagnostics, climate-resilient agriculture, and microbial tools for mining and energy remediation. Key research partners include the University of British Columbia (UBC), the University of Victoria, and the Michael Smith Genome Sciences Centre. Recent work has targeted areas like precision oncology and sustainable forestry genomics. Gill oversees the foundation's strategic direction alongside Board Chair Peggy Johnston and CFO Tony Brooks, who also leads the Entrepreneurship & Commercialization portfolio. Genome BC operates from its Vancouver headquarters, with a specialized research footprint at the UVic-Genome BC Proteomics Centre in Victoria. The organization is embedded in the provincial innovation ecosystem through active memberships in LifeSciences BC and the Greater Vancouver Board of Trade. In 2023, Genome Canada and provincial partners renewed multi-year funding commitments to sustain national genomics platforms (per Genome Canada, 2023). Genome BC's structural differentiation lies in its role as a public-purpose venture catalyst rather than a return-seeking institutional investor. It operates on a co-funding mandate with federal and provincial governments, absorbing early-stage scientific risk to de-risk opportunities for later industrial adoption. This model links academic labs directly with industry through a single, regionally focused funding platform — a governance structure distinct from both pure grant-making bodies and private venture firms.

General information

Firm type

Endowment / Foundation

Year founded

2000

Location

Region

North America

Country

Canada

City

Vancouver

Corporate office

400-575 West 8th Avenue, Vancouver, BC V5Z 0C4, Canada

Additional offices

Victoria, BC, Canada

Principals

Suzanne Gill

President and CEO

Peggy Johnston

Chair of the Board of Directors

Tony Brooks

CFO and VP, Entrepreneurship & Commercialization

Sector focus

Digital HealthAgriTech & FoodTechClimateTechEnergy Transition & Renewables

Frequently asked questions

Who runs investment decisions at Genome BC?

President and CEO Suzanne Gill leads the organization's strategic and investment direction, supported by CFO and VP of Entrepreneurship & Commercialization Tony Brooks. The Board of Directors, chaired by Peggy Johnston, provides governance oversight. Investment decisions follow a co-funding model with federal and provincial partners Genome Canada and the Province of British Columbia.

How does Genome BC source its deal flow?

Deal flow originates through academic partnerships with institutions like the University of British Columbia, the University of Victoria, and the Michael Smith Genome Sciences Centre. As a regional catalyst, Genome BC identifies high-potential genomics research projects and entrepreneurial ventures within British Columbia's life sciences ecosystem, often co-funded with Genome Canada.

Is Genome BC a family office or a venture firm?

Genome BC is a not-for-profit organization that functions as a public-purpose venture catalyst. It is not a family office or a traditional return-seeking venture firm. It deploys government co-investment to advance genomics research and commercialization across health, agriculture, and natural resources in British Columbia.

Which sectors does Genome BC explicitly avoid?

Genome BC's mandate is focused on applying genomics to seven sectors: human health, agriculture, forestry, fisheries, energy, mining, and the environment. It does not invest in unrelated technology verticals such as enterprise software, fintech, or consumer internet, and its scope is bounded by the province of British Columbia.

How does Genome BC structure its investments?

Genome BC uses a mix of research grants and direct commercialization support, deploying capital into early-stage and venture-stage genomics projects. It does not make fund commitments as a limited partner. The organization co-invests alongside Genome Canada and the Province of British Columbia to de-risk scientific ventures for eventual industrial adoption.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on endowments & foundations?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Vancouver Endowment / Foundation profiles